Vertex: More Appealing At A Lower Price, But Don't Rush In (Rating Upgrade)
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...
Zacks Investment Research on MSN1d
Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...
Vertex to Cease Clinical Trials on Diabetes Treatment
Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.
The New York Times16d
What's Going On in This Graph?
What do you wonder? By The Learning Network A new collection of graphs, maps and charts organized by topic and type from our “What’s Going On in This Graph?” feature. By The Learning ...
SurgeGraph Releases Free AI Humanizer Tool For Public Use
Federal Territory of Kuala Lumpur, Malaysia, February 28, 2025 -- SurgeGraph, an AI writing tool focused on helping users grow their traffic ...
Plentisoft: SurgeGraph Releases AI Humanizer Tool for Public Use
SurgeGraph, an AI writing tool focused on helping users grow their traffic through SEO-optimized long-form content, ...
C&EN1mon
How the Orientation of BN Units Influences the Aromaticity of Some Iminobora-Benzenes
Center of Applied Nanoscience (CANS), Facultad de Ciencias Exactas, Universidad Andres Bello, Av. República 275, Santiago 8370146, Chile ...
Investopedia10mon
K-Shaped Recovery: Definition, K-Curve Chart Example, and Causes
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...